Insider Selling: AbbVie (NYSE:ABBV) EVP Sells 40,619 Shares of Company Stock

AbbVie Inc. (NYSE:ABBV – Get Free Report) EVP Jeffrey Stewart sold 40,619 shares of AbbVie stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $293.60, for a total value of $11,925,738.40. Following the sale, the executive vice president directly owned 83,171 shares in the company, valued at approximately $24,419,005.60. The trade was a 32.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

AbbVie Price Performance

ABBV traded down $0.23 on Thursday, reaching $294.75. The company’s stock had a trading volume of 4,825,152 shares, compared to its average volume of 6,312,433. The stock has a market cap of $521.01 billion, a price-to-earnings ratio of 50.73, a price-to-earnings-growth ratio of 1.34 and a beta of 0.20. AbbVie Inc. has a 1 year low of $190.75 and a 1 year high of $302.93. The business’s 50 day moving average is $274.15 and its 200 day moving average is $240.18.

AbbVie (NYSE:ABBV – Get Free Report) last posted its quarterly earnings data on Friday, October 30th. The company reported $3.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.73 by $0.09. AbbVie had a negative return on equity of 450.55% and a net margin of 15.67%. The company had revenue of $17.40 billion for the quarter, compared to the consensus estimate of $17.32 billion. During the same period in the previous year, the business earned $1.86 EPS. AbbVie’s revenue for the quarter was up 10.3% compared to the same quarter last year. As a group, research analysts forecast that AbbVie Inc. will post 13.98 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 16th. Stockholders of record on Friday, January 15th will be given a dividend of $1.82 per share. The ex-dividend date of this dividend is Friday, January 15th. This is an increase from AbbVie’s previous quarterly dividend of $1.73. This represents a $7.28 dividend on an annualized basis and a dividend yield of 2.5%. AbbVie’s dividend payout ratio is 119.10%.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. BNP Paribas Exane upped their price target on shares of AbbVie from $218.00 to $247.00 and gave the company a “neutral” rating in a report on Tuesday, August 11th. Argus raised their price objective on shares of AbbVie from $250.00 to $270.00 in a report on Tuesday, August 4th. Weiss Ratings raised shares of AbbVie from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, October 8th. HSBC upped their target price on shares of AbbVie from $300.00 to $315.00 and gave the company a “buy” rating in a research note on Thursday, September 10th. Finally, Rothschild & Co Redburn upped their target price on shares of AbbVie from $284.00 to $285.00 and gave the company a “buy” rating in a research note on Tuesday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $297.46.

View Our Latest Stock Report on ABBV

Institutional Investors Weigh In On AbbVie

A number of institutional investors have recently made changes to their positions in the company. Meeder Advisory Services Inc. raised its position in shares of AbbVie by 10.2% during the 3rd quarter. Meeder Advisory Services Inc. now owns 56,844 shares of the company’s stock worth $14,870,000 after purchasing an additional 5,256 shares during the period. Benjamin Edwards Inc. grew its stake in AbbVie by 1.1% during the 3rd quarter. Benjamin Edwards Inc. now owns 331,067 shares of the company’s stock worth $86,624,000 after buying an additional 3,745 shares during the last quarter. CacheTech Inc. grew its stake in AbbVie by 13.1% during the 3rd quarter. CacheTech Inc. now owns 5,213 shares of the company’s stock worth $1,364,000 after buying an additional 603 shares during the last quarter. First Trust Advisors LP increased its position in AbbVie by 16.2% in the third quarter. First Trust Advisors LP now owns 930,220 shares of the company’s stock worth $243,336,000 after buying an additional 129,402 shares during the period. Finally, BNP Paribas increased its position in AbbVie by 15.2% in the third quarter. BNP Paribas now owns 91,694 shares of the company’s stock worth $24,025,000 after buying an additional 12,098 shares during the period. 70.23% of the stock is currently owned by institutional investors.

About AbbVie

(Get Free Report)

AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.

Featured Articles

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.